Gabriella Cotugno
Overview
Explore the profile of Gabriella Cotugno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
546
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Troise F, Leoni G, Sasso E, Del Sorbo M, Esposito M, Romano G, et al.
Mol Ther Oncol
. 2024 Apr;
32(1):200760.
PMID: 38596303
Neoantigen (neoAg)-based cancer vaccines expand preexisting antitumor immunity and elicit novel cancer-specific T cells. However, at odds with prophylactic vaccines, therapeutic antitumor immunity must be induced when the tumor is...
2.
Bartolomeo R, Troise F, Allocca S, Sdruscia G, Vitale R, Bignone V, et al.
Vaccines (Basel)
. 2024 Mar;
12(3).
PMID: 38543959
Quality control testing of vaccines, including potency assessment, is critical to ensure equivalence of clinical lots. We developed a potency assay to support the clinical advancement of Nous-209, a cancer...
3.
DAlise A, Leoni G, Cotugno G, Siani L, Vitale R, Ruzza V, et al.
Clin Cancer Res
. 2024 Mar;
30(11):2412-2423.
PMID: 38506710
Purpose: Personalized vaccines targeting multiple neoantigens (nAgs) are a promising strategy for eliciting a diversified antitumor T-cell response to overcome tumor heterogeneity. NOUS-PEV is a vector-based personalized vaccine, expressing 60...
4.
Garzia I, Nocchi L, Avalle L, Troise F, Leoni G, Secli L, et al.
Cancer Immunol Res
. 2024 Feb;
12(4):440-452.
PMID: 38331413
Tumor neoantigens (nAg) represent a promising target for cancer immunotherapy. The identification of nAgs that can generate T-cell responses and have therapeutic activity has been challenging. Here, we sought to...
5.
Secli L, Leoni G, Ruzza V, Siani L, Cotugno G, Scarselli E, et al.
Int J Mol Sci
. 2023 Dec;
24(23).
PMID: 38068911
The aim of personalized cancer vaccines is to elicit potent and tumor-specific immune responses against neoantigens specific to each patient and to establish durable immunity, while minimizing the adverse events....
6.
DAlise A, Nocchi L, Garzia I, Secli L, Infante L, Troise F, et al.
Front Immunol
. 2023 May;
14:1156714.
PMID: 37180141
Introduction: Virus vectored genetic vaccines (Vvgv) represent a promising approach for eliciting immune protection against infectious diseases and cancer. However, at variance with classical vaccines to date, no adjuvant has...
7.
Secli L, Infante L, Nocchi L, De Lucia M, Cotugno G, Leoni G, et al.
J Immunother Cancer
. 2023 Apr;
11(4).
PMID: 37117006
Background: Tumor microenvironment (TME) represents a critical hurdle in cancer immunotherapy, given its ability to suppress antitumor immunity. Several efforts are made to overcome this hostile TME with the development...
8.
Gentile C, Finizio A, Froechlich G, DAlise A, Cotugno G, Amiranda S, et al.
Int J Mol Sci
. 2021 Dec;
22(24).
PMID: 34948316
Background: Oncolytic viruses are immunotherapeutic agents that can be engineered to encode payloads of interest within the tumor microenvironment to enhance therapeutic efficacy. Their therapeutic potential could be limited by...
9.
DAlise A, Leoni G, De Lucia M, Langone F, Nocchi L, Tucci F, et al.
J Immunother Cancer
. 2021 Nov;
9(11).
PMID: 34824160
Background: A number of different immune pathways are involved in the effective killing of cancer cells, collectively named as the 'Cancer Immunity Cycle'. Anti-PD-1 checkpoint blockade (CPB) therapy is active...
10.
Leoni G, DAlise A, Tucci F, Micarelli E, Garzia I, De Lucia M, et al.
Vaccines (Basel)
. 2021 Aug;
9(8).
PMID: 34452005
Neoantigens are tumor-specific antigens able to induce T-cell responses, generated by mutations in protein-coding regions of expressed genes. Previous studies demonstrated that only a limited subset of mutations generates neoantigens...